Rajesh Bandekar Selected Research

siltuximab

1/2019	Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
10/2015	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
5/2015	Dose selection of siltuximab for multicentric Castleman's disease.
1/2015	A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
8/2014	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
4/2014	A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
1/2014	Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rajesh Bandekar Research Topics

Disease

5	Multiple Myeloma 01/2021 - 01/2014
4	Smoldering Multiple Myeloma 01/2021 - 01/2014
2	Infections 01/2019 - 01/2015
2	Prostatic Neoplasms (Prostate Cancer) 07/2017 - 12/2016
2	Multi-centric Castleman's Disease 05/2015 - 08/2014
1	Anemia 10/2015
1	Castleman Disease (Castleman's Disease) 10/2015
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 05/2015
1	Neutropenia 01/2015
1	Thrombocytopenia (Thrombopenia) 01/2015
1	Respiratory Tract Infections (Respiratory Tract Infection) 08/2014
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 08/2014
1	Sepsis (Septicemia) 08/2014
1	Anaphylaxis (Anaphylactic Shock) 08/2014
1	Neoplasms (Cancer) 04/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2014
1	Heart Diseases (Heart Disease) 01/2014
1	Monoclonal Gammopathy of Undetermined Significance 01/2014
1	Otitis Media 06/2005

Drug/Important Bio-Agent (IBA)

7	siltuximabIBA 01/2019 - 01/2014
6	Monoclonal AntibodiesIBA 01/2021 - 01/2014
3	Interleukin-6 (Interleukin 6)IBA 01/2019 - 08/2014
2	daratumumabIBA 01/2021 - 01/2020
2	apalutamideIBA 07/2017 - 12/2016
2	InterleukinsIBA 08/2014 - 04/2014
1	antiarrhythmic peptide (AAP)IBA 07/2017
1	Prednisone (Sone)FDA LinkGeneric 07/2017
1	Abiraterone AcetateIBA 07/2017
1	Androgen Receptor AntagonistsIBA 12/2016
1	Biomarkers (Surrogate Marker)IBA 10/2015
1	HepcidinsIBA 10/2015
1	Bortezomib (Velcade)FDA Link 01/2015
1	ErbB Receptors (EGF Receptor)IBA 04/2014
1	Azithromycin (Zithromax)FDA LinkGeneric 06/2005
1	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 06/2005
1	Amoxicillin (Wymox)FDA LinkGeneric 06/2005

Therapy/Procedure

2	Castration 07/2017 - 12/2016
1	Aftercare (After-Treatment) 07/2017